Impact of response patterns for patients with advanced acral melanoma treated with anti-programmed death-1 monotherapy.

Li ZhouLizhi ShaoShunyu GaoChuanliang CuiZhihong ChiXinan ShengBixia TangLili MaoBin LianXieqiao YanXuan WangXue BaiSiming LiJun GuoLu Si

Published in: The British journal of dermatology (2023)

HPD during immunotherapy serves as an essential biomarker of poor prognosis in advanced AM. Metastases in different sites respond distinctively to immunotherapy. Clinically heterogeneous responses to immunotherapy affect the outcome of patients. A predictive model was built to distinguish the prognosis of acral melanoma under immunotherapy.

Keyphrases

poor prognosis
long non coding rna
end stage renal disease
newly diagnosed
ejection fraction
peritoneal dialysis
randomized controlled trial
clinical trial
patient reported outcomes
patient reported